Angioplasty Balloons are essential devices used to treat cardiovascular conditions like coronary artery disease (CAD), peripheral artery disease (PAD), and atherosclerosis by expanding narrowed vessels. Available in normal, drug-coated, cutting, and scoring types, they are utilized in hospitals, ambulatory surgical centers, and other settings. The market is driven by the rising prevalence of cardiovascular diseases, with the World Health Organization reporting 17.9 million annual deaths - 32% of global mortality - 85% from heart attacks and strokes. Aging populations, projected to reach 2.1 billion over 60 by 2050, increase disease risk, while minimally invasive preferences and innovations like drug-eluting balloons enhance treatment efficacy and market growth.
In March 2024, Boston Scientific gained FDA approval for the AGENT Drug-Coated Balloon for in-stent restenosis.
In March 2024, a BIDMC-led trial led to FDA approval of coronary DCBs, improving CAD treatment outcomes.
This product will be delivered within 1-3 business days.
Market Size and Growth Forecast
The global angioplasty balloons market is anticipated to reach between USD 1.4 billion and USD 1.8 billion in 2025, with a compound annual growth rate (CAGR) of 3.5% to 4.9% through 2030, reflecting cardiovascular disease burdens and technological progress.Regional Analysis
- North America: The U.S. leads with high CAD prevalence, while Canada focuses on advanced interventions.
- Europe: Germany, France, and the UK dominate, driven by aging demographics and healthcare systems.
- Asia Pacific: China and India see rapid growth due to rising risk factors, while Japan emphasizes elderly care.
- Rest of the World: Brazil expands cardiovascular care, and the Middle East, notably the UAE, invests in premium devices.
Application Analysis
- Hospitals: Projected growth of 3.5-4.5%, driven by complex procedures. Trends focus on advanced balloons.
- Ambulatory Surgical Centers: Expected growth of 4.0-5.0%, linked to outpatient trends. Developments emphasize efficiency.
- Others: Growth at 3.0-4.0%, including specialty centers. Advances prioritize versatility.
Product Type Analysis
- Normal Balloons: Anticipated growth of 3.0-4.0%, valued for simplicity. Trends focus on durability.
- Drug Coated Balloons: Expected growth of 4.5-5.5%, key for reducing restenosis. Advances highlight drug delivery.
- Cutting Balloons: Growth at 3.5-4.5%, used for calcified lesions. Developments enhance precision.
- Scoring Balloons: Projected growth of 3.5-4.5%, improving vessel preparation. Trends emphasize flexibility.
Key Market Players
Key players include Medtronic, innovating in cardiovascular devices; Boston Scientific Corporation, advancing drug-coated balloons; Abbott, enhancing vascular solutions; Philips, integrating imaging; B. Braun, offering reliable tools; Terumo Medical Corporation, focusing on precision; Cook Medical, providing intervention devices; Cardinal Health, targeting healthcare; C. R. Bard, advancing balloons; and Biotronik, improving outcomes. These firms drive market growth through innovation.Porter's Five Forces Analysis
- Threat of New Entrants: Moderate, due to R&D costs and regulatory barriers, though niche players can enter.
- Threat of Substitutes: Moderate, with stents competing, though balloons offer unique benefits.
- Bargaining Power of Buyers: Moderate, as hospitals seek cost-effective options, balanced by efficacy needs.
- Bargaining Power of Suppliers: Low, due to multiple material suppliers.
- Competitive Rivalry: High, with firms competing on efficacy and innovation.
Market Opportunities and Challenges
Opportunities:
- Cardiovascular diseases causing 17.9 million deaths annually drive demand.
- Aging populations, growing to 2.1 billion by 2050, increase needs.
- Minimally invasive trends boost adoption, while innovations like Teleflex’s 2024 Ringer PBC and Boston Scientific’s 2024 AGENT DCB enhance outcomes.
- Emerging markets offer growth with healthcare improvements.
Challenges:
- High costs limit adoption in low-income regions despite disease prevalence.
- Regulatory delays for new balloons pose hurdles.
- Competition from stents and alternative therapies pressures market share.
- Market News
In March 2024, Boston Scientific gained FDA approval for the AGENT Drug-Coated Balloon for in-stent restenosis.
In March 2024, a BIDMC-led trial led to FDA approval of coronary DCBs, improving CAD treatment outcomes.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 Industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Forecast Angioplasty Balloon Market in North America (2020-2030)
Chapter 10 Historical and Forecast Angioplasty Balloon Market in South America (2020-2030)
Chapter 11 Historical and Forecast Angioplasty Balloon Market in Asia & Pacific (2020-2030)
Chapter 12 Historical and Forecast Angioplasty Balloon Market in Europe (2020-2030)
Chapter 13 Historical and Forecast Angioplasty Balloon Market in MEA (2020-2030)
Chapter 14 Summary For Global Angioplasty Balloon Market (2020-2025)
Chapter 15 Global Angioplasty Balloon Market Forecast (2025-2030)
Chapter 16 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Medtronic
- Boston Scientific Corporation
- Abbott
- Philips
- B. Braun
- Terumo Medical Corporation
- Cook Medical
- Cardinal Health
- C. R.Bard
- Biotronik
